Find disease awareness content and relevant supporting materials

Marinus Pharmaceuticals, Inc. announced topline results from the Phase III double-blind, randomized, placebo-controlled RAISE trial (NCT04391569) evaluating the safety and efficacy of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE)  RSE, in which prolonged continuous or rapidly recurring seizures do not respond to first- and second-line therapy, is associated with significant morbidity and mortality

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis

Discover the differences between new-onset and persistent epilepsy in the elderly. Our 10-year retrospective analysis reveals that new-onset epilepsy patients, often presenting with status epilepticus, face higher risks and more stroke-related factors. Despite these challenges, they may require fewer antiepileptic drugs compared to those with persistent epilepsy.

Introduction: Ketamine exhibits antidepressant properties in treatment-resistant depression (TRD) with some concern over its cardiovascular safety and tolerability issues.

Objective: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension.

Areas covered: This review will briefly discuss current treatment options for TRD, then review esketamine.

PharmaTher Holdings Ltd. announced receipt of a Complete Response Letter (“CRL”) for its Priority Original Abbreviated New Drug Application for Ketarx (ketamine) that was accepted by the FDA and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.

The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.

Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side effects.

This study investigates the modulation of amygdala reactivity following rapidly acting interventions for major depression, specifically electroconvulsive therapy (ECT) and ketamine treatment, and their impact on emotion processing.